VKTX 📈 Viking Therapeutics - Overview

Viking Therapeutics Inc, a clinical-stage biopharmaceutical company, is dedicated to developing innovative therapies for metabolic and endocrine disorders, which are significant public health concerns. The company's research and development efforts focus on creating novel treatments that address the underlying causes of these diseases, with the goal of improving patient outcomes and quality of life. Viking Therapeutics' lead drug candidate, VK2809, is a thyroid hormone receptor beta agonist that has shown promise in treating non-alcoholic steatohepatitis and non-alcoholic fatty liver disease, both of which are increasingly prevalent and can lead to severe liver damage if left untreated.

VK2809, which is currently in Phase IIb clinical trials, has the potential to become a first-in-class treatment for these conditions, offering a new therapeutic option for patients who currently have limited treatment choices. In addition to VK2809, Viking Therapeutics has a diverse pipeline of drug candidates, including VK5211, a selective androgen receptor modulator being developed to treat patients recovering from non-elective hip fracture surgery, and VK0612, a potential treatment for type 2 diabetes. The company is also exploring the therapeutic potential of VK2735, a dual agonist of the glucagon-like peptide, and VK0214, a tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is being investigated as a treatment for X-linked adrenoleukodystrophy.

Viking Therapeutics was founded in 2012 and is headquartered in San Diego, California, a hub for biotechnology and pharmaceutical research. The company's experienced management team and research staff are committed to advancing the development of its pipeline candidates and bringing new treatments to market. With a strong focus on research and development, Viking Therapeutics is well-positioned to become a leader in the biopharmaceutical industry, addressing significant unmet medical needs and improving the lives of patients with metabolic and endocrine disorders. The company's common stock is listed on the NASDAQ stock exchange under the ticker symbol VKTX, and its website provides detailed information on its research and development activities, pipeline candidates, and corporate governance.